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There is a dearth of high quality evidence to guide antibiotic
therapy for pulmonary exacerbations of cystic fibrosis (CF) and
so we read with interest the paper by Adeboyeku et al. [1],
which compares twice and three times daily regimens for
ceftazidime and tobramycin. Unfortunately this paper contains
important methodological flaws and describes the existing
literature in a manner which is misleading.
The trial is designed to show the superiority of one regimen
over the other. In fact, as the authors point out in their
discussion, the correct design would have been an equivalence
study. The authors cannot therefore conclude that the regimens
which they compared have equivalent efficacy – rather they
have conducted a study which is too small to show any
difference there might be between regimens.
The authors summarise the results of the TOPIC trial [2] by
saying the trial “…reported equal efficacy between once and
three-times daily tobramycin given with ceftazidime, with a
trend to less nephrotoxicity in children.”We urge the authors to
read the TOPIC paper again. The TOPIC trial was a well
designed equivalence trial and so the conclusion that once and
three times daily tobramycin have an equivalent efficacy is
robust. However, the study also showed that once daily
treatment was less nephrotoxic – a finding which was both
statistically significant and clinically important. In children,
there was a significant difference, in favour of once daily
treatment, both in the change in plasma creatinine and in urinary
N-acetyl-beta-D glucosaminidase (NAG) – a biomarker of renal
tubular damage. In the combined group (children and adults),
the difference was seen in NAG alone. However, NAG is
arguably the more important measure of nephrotoxicity, as it
measures renal tubular damage and tobramycin has its toxic
effects on the renal tubule.
The authors suggest that a tobramycin dose of 10 mg/kg/day
may be associated with ototoxicity. The TOPIC study used
10 mg/kg/day, with a maximum total daily dose of 660 mg. It is
important not to exceed this maximum dose and this limit is
currently recommended in national guidelines [3]. We have
reported data on 168 patients who underwent standard pure tone
audiogram, as part of the TOPIC study [4], and found no1569-1993/$ - see front matter © 2011 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2011.03.010measureable change in hearing during treatment (on either
regimen) and no difference between regimens.
Current guidelines in the UK [3] and the US [5] recommend
a once daily tobramycin for pulmonary exacerbations of CF.
Practice has changed in line with these guidelines. A UK
national survey, which we conducted in 2002, showed that once
daily aminoglycosides were used by only 17% of UK CF
centres [6] whereas by 2006, once daily usage had risen to 68%
(data unpublished). Adeboyeku et al. have not compared their
twice daily approach with the current, widely recommended,
once daily tobramycin regimen and have provided safety data in
only a small group (only 31 patients had audiometry). It would
be unwise therefore for anyone to change practice, based on
these limited data.
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